Nanomix (Nanomix) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of May. 23, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Nanomix Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Nanomix's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of Nanomix's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Medical Devices subindustry, Nanomix's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanomix's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nanomix's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Nanomix's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.

Nanomix (OTCPK:NNMX) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Nanomix Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Nanomix's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanomix (Nanomix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nanomix Corp (OTCPK:NNMX) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Comparable Companies

Traded in Other Exchanges

N/A

Address

2121 Williams Street, San Leandro, CA, USA, 94577

Website

https://www.nanomixdx.com

Nanomix Corp develops, manufactures, and commercializes point-of-care diagnostic tests that are used to detect or monitor diseases. Its products include The Nanomix eLab System, COVID-19 Rapid Antigen Panel, and Critical Infection and Host Response. The company's products improve healthcare delivery by bringing the diagnostic information to the point of initial patient interaction, whether in the hospital or settings such as nursing facilities, elderly homes, urgent care centers, airports, schools, and more.

Executives

Chris Hetterly	officer: Chief Financial Officer	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Garrett Gruener	director, 10 percent owner	ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111
Thomas Schlumpberger	director, officer: CEO	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
Vidur Sahney	officer: Chief Operating Officer	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
John Hardesky	officer: Chief Commercial Officer	C/O NANOMIX CORPORATION, 2121 WILLIAMS STREET, SAN LEANDRO CA 94577
David Ludvigson	director, officer: CEO and President	BLACK PEARL INC, 400 SECOND ST STE 450, SAN FRANCISCO CA 94107
Gregory T Schiffman	director	1030 NW JOHNSON ST, UNIT 608, PORTLAND OR 97209
Loraine Upham	officer: Chief Operating Officer	C/O BOSTON THERAPEUTUCS INC., 354 MERRIMACK ST, #4, LAWRENCE MA 01843
Carl W Rausch	director, officer: CEO
Alan M Hoberman	director	6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Cheng Conroy Chi-heng	director	ADVANCE PHARMACEUTICAL CO LTD, 3/F, GMP CENTRE, 12 DAI FU STREET, TAI PO K3 280
Anthony Don Squeglia	officer: Chief Financial Officer	PRO-PHARMACEUTICALS, INC., 7 WELLS AVENUE, SUITE 34, NEWTON MA 02459
Neill Sydney Colin	director	C/O AXONYX INC, 500 SEVENTH AVE 1OTH FLOOR, NEW YORK NY 10018
Jonathan B Rome	officer: Chief Operating Officer (3)	178 WEST SADDLE RIVER ROAD, SADDLE RIVER NJ 07458
Rom E Eliaz	director	33 KACHAL STREET, LEHAVIM L3 85338